Go back to News
NEWS
GA_P advises Impact Partners on Top Doctors Series B financing round
14 October, 2021
Gómez-Acebo & Pombo has advised Impact Partners on its investment in Top Doctors. The Series B financing round, led by Impact Partners and in which the Institut Català de Finances (ICF) also participated, amounted to €11.2 million.
Top Doctors is a startup that offers a digital tool that allows users to access more than 90,000 experts in 50 medical specialties, while providing healthcare professionals with telemedicine solutions, online presence and brand image. The company expects to close the year with a turnover of 16 million euros, 30% more than in 2020. The capital increase will allow the company to consolidate its medical platform in the countries where it already operates in Europe, Latin America and the Middle East.
The GA_P team was formed by Álvaro Mateo and Rocío García de Oteyza, partner and associate in the Corporate area.
See complete article in CincoDías
Top Doctors is a startup that offers a digital tool that allows users to access more than 90,000 experts in 50 medical specialties, while providing healthcare professionals with telemedicine solutions, online presence and brand image. The company expects to close the year with a turnover of 16 million euros, 30% more than in 2020. The capital increase will allow the company to consolidate its medical platform in the countries where it already operates in Europe, Latin America and the Middle East.
The GA_P team was formed by Álvaro Mateo and Rocío García de Oteyza, partner and associate in the Corporate area.
See complete article in CincoDías
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
¡NEW! 
PUBLICATION
2 days ago
Automotive and Sustainable Mobility No. 32
Summary of legislative and jurisprudential developments relating to the automotive sector.
2 days ago 
PUBLICATION
28 Oct, 2026
Public access to personal details of minority shareholders in a company limited by shares (CJEU, First Chamber, 3 September 2026; Case C-798/24 [Jautiva])
The Court of Justice of the European Union, in a reference for a preliminary ruling, has examined whether EU law precludes national legislation requiring public disclosure of personal data of shareholders (including minority shareholders) of a public limited company when access to such data is not subject to any requirement, such as proof of a legitimate interest.
28 Oct, 2026
PUBLICATION
23 Sep, 2026
Paradoxes of non-binding and entire agreement clauses being meta-clauses
Inasmuch as functioning as meta-clauses, non-binding and entire agreement clauses are paradoxical in a number of ways.
23 Sep, 2026
PUBLICATION
21 Sep, 2026
Pharma & Healthcare No. 50
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
21 Sep, 2026
PUBLICATION
31 Jul, 2026
Automotive and Sustainable Mobility No. 31
Summary of legislative and jurisprudential developments relating to the automotive sector.
31 Jul, 2026
PUBLICATION
08 Jul, 2026
Are company directors directly liable for torts attributable to the company?
Debt from liability in tort for third-party damage or loss arises directly against the directors, without prejudice to the fact that, pursuant to Article 38 CC, it also arises simultaneously against the company, to which the non-contractual acts or omissions of its directors are also attributed. This is so true that the liable company (in debt, for example, with the tax authorities as the person liable for the surcharge and the tax penalty owed) may bring an action for contribution against its directors after settling the debt.
08 Jul, 2026
PUBLICATION
23 Jun, 2026
Pharma & Healthcare No. 49
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
23 Jun, 2026
PUBLICATION
18 Jun, 2026
Royal Decree 415/2026: key aspects of the new health technology assessment system
Royal Decree 415/2026 establishes a unified framework for the assessment of health technologies in Spain, distinguishing between the technical assessment and the administrative decision regarding funding, pricing or inclusion in the service catalogue, and incorporating the requirements of Regulation (EU) 2021/2282. The aspect that raises the most legal questions in this new piece of legislation is the connection between the assessment regulated by the Royal Decree and the procedures for funding, pricing, and inclusion in the service catalogue.
18 Jun, 2026
PUBLICATION
09 Jun, 2026
The “serious risk” of financial assistance (Supreme Court (First Chamber) Judgment of 5 May 2026)
This paper critically analyses the Supreme Court ruling of 5May 2026, which applies the prohibition on financial assistance to a case involving the sale of treasury shares with deferred payment to the shareholders of the assisting company.
09 Jun, 2026